SOBI
SWTOYDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
Avatrombopag
Chemotherapy-induced Thrombocytopenia
Avatrombopag Oral Tablet
Immune Thrombocytopenia
Emapalumab
Cytopenia
Pacritinib
Waldenström Macroglobulinemia
Loncastuximab Tesirine and Epcoritamab
Aggressive Diffuse Large B-cell Lymphoma
Fludarabine and Dexamethasone
Primary Immune Regulatory Disorder
Hydroxyurea
Leukemia, Myelomonocytic, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Avatrombopag | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
Avatrombopag Oral Tablet | Phase 3 | Immune Thrombocytopenia | - | - |
Emapalumab | Phase 2 | Cytopenia | - | - |
Pacritinib | Phase 2 | Waldenström Macroglobulinemia | - | - |
Loncastuximab Tesirine and Epcoritamab | Phase 2 | Aggressive Diffuse Large B-cell Lymphoma | - | - |
Fludarabine and Dexamethasone | Phase 2 | Primary Immune Regulatory Disorder | - | - |
Hydroxyurea | Phase 2 | Leukemia, Myelomonocytic, Chronic | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SOBI's drug pipeline?→
CatalystAlert tracks 7 drug candidates in SOBI's (SWTOY) pipeline across Phase 3, Phase 2. Its lead program is Avatrombopag (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SOBI's next FDA catalyst?→
SOBI's (SWTOY) next tracked catalyst is a Phase 2 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SWTOY biotech catalysts?→
Add SWTOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SOBI's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.